AGEN: שווי שוק לרווח נקי מותאם קצב צמיחה Agenus

Agenus faces high antibody synthesis costs and pressure within the oncology segment, yet it monetizes its patents through royalties from major partners. Comparing the P/E ratio with growth rates visualizes this balance, where 0.00 reflects the latest metric value. Consistent waste utilization control and center energy efficiency support the long-term sustainability of the business.

To identify fundamental stability drivers, the PEG ratio is utilized, where values below one signal that the asset is undervalued. By analyzing this indicator of undervaluation relative to growth, an investor assesses the fairness of the market value of Agenus (AGEN) considering the prospects for commercializing its own vaccines and revenues from partnerships in the field of immuno-oncology.